Design Therapeautics, Inc.

DSGN04 Dec 2024
Healthcare
$5.99
+0.02 (+1.50%)
Lowest Today
$5.99
Highest Today
$6.1
Today’s Open
$5.99
Prev. Close
$5.99
52 Week High
$7.77
52 Week Low
$2.25
To Invest in Design Therapeautics, Inc.

Design Therapeautics, Inc.

Healthcare
DSGN04 Dec 2024
+0.02 (+1.50%)
1M
3M
6M
1Y
5Y
Low
$5.99
Day’s Range
High
$6.1
5.99
52 Week Low
$2.24
52-Week Range
52 Week High
$7.77
2.24
1 Day
-
1 Week
-0.16%
1 month return
+12.61%
3 month return
+25.1%
6 month return
+47.29%
1 Year return
+144.08%
3 Years return
-64.29%
5 Years return
-
10 Years return
-
Institutional Holdings
SR ONE CAPITAL MANAGEMENT, LP
11.53
Logos Global Management LP
7.45
BlackRock Inc
4.07
Baker Bros Advisors LP
3.08
Point72 Asset Management, L.P.
2.83
TANG CAPITAL MANAGEMENT LLC
2.62
Vanguard Group Inc
2.46

Market Status

Fundamentals
Market Cap
355.58 mln
PB Ratio
1.41
PE Ratio
0
Enterprise Value
104.03 mln
Total Assets
289.64 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
Organisation
Design Therapeautics, Inc.
Employees
54
Industry
Biotechnology
CEO
Mr. Pratik  Shah Ph.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities